Apellis Pharma

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic and complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Apellis Pharma reports strong Q1 revenue, eyes U.S. expansion

Apellis Pharma's Q1 2023 performance showcased strong revenue from SYFOVRE and EMPAVELI, with positive feedback and demand in the market.
While facing challenges like safety concerns and European commercialization, the company is focused on expanding market reach and driving awareness.
Opportunities lie in making SYFOVRE widely available, promoting patient education, and potential approval in Europe for further growth.

Apellis Pharma reports robust Q2 sales amidst safety event challenges

Apellis Pharma's Q2 performance highlighted strong sales, positive product efficacy, and proactive response to safety events
Despite challenges with rare safety events, the company's strengths in product credibility, manufacturing quality, and market acceptance shine through
Opportunities lie in enhancing physician education, exploring financing options, and leveraging positive efficacy evolution for market growth
Overall, Apellis Pharma's strategic measures position it well to navigate challenges, capitalize on opportunities, and maintain market confidence

Apellis Pharma reports mixed Q3 results, eyes European expansion

Apellis Pharma's Q3 performance showed strong revenue from key products but also highlighted the need for cost-saving measures. The company's focus on global expansion and product launches in Europe presents growth opportunities amidst market challenges.

Apellis Pharma reports strong Q4 earnings amidst market challenges

Apellis Pharma delivered strong financial results in Q4 2023, driven by the success of SYFOVRE and EMPAVELI in the U.S., while navigating challenges in the EU market and competitive landscape.
The company's strategic focus on patient access, market leadership, and R&D advancement positions it for continued growth and innovation in precision medicine, supported by robust engagement with medical communities.
Opportunities lie in expanding market share through bilateral treatments, advancing pipeline programs, and leveraging compliance and real-world data to strengthen Apellis Pharma's position as a leading provider of GA therapies.
Addressing challenges such as market competition, regulatory processes, and financial performance will be crucial for Apellis Pharma to sustain growth, optimize revenue, and drive profitability in the future.

Apellis Pharma reports robust Q1 performance and eyes expansion

Apellis Pharma (APLS) showcased strong financial performance and product success in Q1 2024, with plans for expansion and upcoming study data.
Despite challenges like a negative CHMP opinion and safety concerns, opportunities in education, expansion, and market penetration are on the horizon.
The company's commitment to shareholder value, financial stability, and milestone achievements sets a positive outlook for the future.

Apellis Pharma reports robust Q2 earnings, eyes market expansion

Apellis Pharma's Q2 performance reflects strong revenue growth and market leadership, supported by successful product sales and strategic initiatives.
While facing competition and challenges in market share retention, the company's focus on expansion and financial strength bode well for future growth.
Opportunities in new indications, market expansion, and pipeline development position Apellis Pharma for continued value creation for patients and shareholders.

Apellis Pharma reports robust Q3 performance amidst market challenges

Apellis Pharma's Q3 performance reflects strong demand for SYFOVRE and strategic initiatives to drive market share.
While facing challenges such as gross to net adjustments and market dynamics, the company remains optimistic about future growth opportunities.
By leveraging strengths in product efficacy and real-world data, Apellis Pharma aims to expand globally and enhance profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Apellis business and prospects, resulting in its stock trading at inflated prices.

APLS INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock?

Apellis Pharmaceuticals, Inc. (APLS) Up 67.8% Since Last Earnings Report: Can It Continue?

Apellis (APLS) plans to initiate restructuring plans to strengthen its commercial portfolio and curb cash burn.

Apellis (APLS) Dips on Layoffs Amid Syfovre Safety Issues

Apellis Pharmaceuticals (NASDAQ: APLS ) layoffs are a hot topic on Tuesday as the commercial-stage biopharmaceutical company prepares for job cuts. Apellis Pharmaceuticals has announced that it will be laying off 25% of its workforce in the third quarter of the year.

Apellis Layoffs 2023: What to Know About the Latest APLS Job Cuts

WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (the “Company”), a global biopharmaceutical company and leader in complement, today announced a corporate restructuring to drive growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), positioning Apellis for long-term success. This restructuring will include cost reduction initiatives that align with the Company's near-term priorities and are expected to result in up to $300 million in total cost savings through 2024.

Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success

NEW YORK , Aug. 28, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) alleging that the Company violated federal securities laws. Class Period: January 28, 2021 to July 28, 2023 Lead Plaintiff Deadline: October 2, 2023 No obligation or cost to you.

SHAREHOLDER ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 2, 2023 in the Class Action Filed on Behalf of Apellis Pharmaceuticals, Inc.(APLS) Shareholders

SAN DIEGO , Aug. 25, 2023 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Apellis class action lawsuit, captioned Soderberg v. Apellis Pharmaceuticals, Inc., No.

APLS INVESTOR ALERT: Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK , Aug. 25, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates inclusive (the "Class Period"), of the important October 2, 2023 lead plaintiff deadline. SO WHAT: If you purchased Apellis common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS

APLS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Apellis Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Apellis Class Action Lawsuit

Revance Therapeutics

SAGE Therapeutics

In the financial markets, not everything always goes up, not everything always goes down. The fluctuations in the share prices of listed companies are constant.

3 Very Oversold Pharma Stocks to Buy Right Now

The shares of Apellis Pharmaceuticals Inc (NASDAQ:APLS) are soaring, after the biopharmaceutical concern identified the potential cause of an issue with its eye disorder treatment, Syfovre, which treats geographic atrophy.

Biopharmaceutical Stock Soars on Positive Drug Update

Apellis' (APLS) shares rise as the company provides updates on safety concerns regarding Syfovre, approved for the treatment of geographic atrophy.

Apellis (APLS) Updates on Safety Concerns for Syfovre

Shares of APLS stock rocketed Wednesday after Apellis identified the potential culprit behind inflammation following its drug, Syfovre.

Apellis Soars 28% After Identifying Potential Culprit Behind Eye Drug Safety Woes

Apellis Pharmaceuticals (NASDAQ: APLS ) stock is on the rise Wednesday after the biopharmaceutical company announced an update on injection kits. The big news here is new guidelines for the use of its SYFOVRE injection kits.

Why Is Apellis Pharmaceuticals (APLS) Stock Up 23% Today?

Apellis Pharmaceuticals Inc. shares APLS, -2.26% jumped 30% premarket on Wednesday after the company identified a potential cause for a rare but serious side effect linked with its Syfovre injection for age-related macular degeneration. Structural variations were found in a certain filter needle used to withdraw treatment from the vial when preparing the injection, the company said in a release late Tuesday.

Apellis Pharmaceuticals stock surges after investigation finds needles are potential cause of injection side effect

Apellis Pharmaceuticals Inc (NASDAQ:APLS) jumped some 30% in Wednesday's premarket after last night updating investors on an ongoing safety review of injection kits, used with SYFOVRE, its treatment for eye disease. A review was previously launched after reports of rare side effects - a form of eye inflammation known as retinal vasculitis.

Apellis Pharmaceuticals stock jumps on safety review update

WALTHAM, Mass., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (“the Company”) today provided an update on injection kits supplied by Apellis and an update on the rare events of retinal vasculitis reported in real-world treatment with SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Apellis Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE® (pegcetacoplan injection)

Bristol-Myers

GlaxoSmithKline

Pharmaceutical stocks can bring you from rags to riches — and back to rags again. The truth is the innovative sector can function similarly to a lottery.

3 Sorry Pharma Stocks to Sell in August Before It's Too Late

Deciphera Pharmaceuticals

Recursion Pharmaceuticals

Biotech stocks may offer some of the most explosive opportunities on the market. For one, we have millions of baby boomers demanding better care.

Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now

NEW YORK, NY / ACCESSWIRE / August 21, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Apellis Pharmaceuticals, Inc. ("Apellis") (NASDAQ:APLS) between January 28, 2021 and July 28, 2023. If you suffered a loss, contact us at the link below.

APLS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Apellis Pharmaceuticals, Inc.

LOS ANGELES, CA / ACCESSWIRE / August 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Apellis Pharmaceuticals, Inc. ("Apellis" or "the Company") (NASDAQ: APLS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 28, 2021 and July 28, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before October 2, 2023.

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Apellis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 2, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Apellis Pharmaceuticals, Inc. (“Apellis” or the “Company”) (NASDAQ: APLS) common stock between January 28, 2021 and July 28, 2023, inclusive (the “Class Period”). If you suffered a loss on your Apellis investments or would like to inquire about potentia.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)

NEW YORK , Aug. 17, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) between January 28, 2021 and July 28, 2023, both dates inclusive (the "Class Period"), of the important October 2, 2023 lead plaintiff deadline. SO WHAT: If you purchased Apellis common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Apellis Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - APLS

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming October 2, 2023 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Apellis Pharmaceuticals, Inc. (“Apellis” or the “Company”) (NASDAQ: APLS) common stock between January 28, 2021 and July 28, 2023, inclusive (the “Class Period”). Investors suffering losses on their Apellis investments are encouraged to contact the Law Offices of Howard G. Smith to discuss.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. (APLS)

NEW YORK , Aug. 17, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. ("Apellis" or the "Company") (NASDAQ: APLS) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Apellis investors who were adversely affected by alleged securities fraud between January 28, 2021 and July 28, 2023.

News for Apellis Pharma Stock (APLS)